The Avea™ VG is designed to use the lowest possible pressure to maintain the desired exhaled tidal volume (Vte). 46% of ventilated neonatal patients experience neonatal respiratory distress syndrome (nRDS). Only 9% of ventilated neonates are treated with Volume Guarantee (VG).

**Robust technology for vulnerable infants**

The Avea™ VG is designed to use the lowest possible pressure to maintain the desired exhaled tidal volume (Vte).

**Volume Guarantee**
- VG manages leaks up to 62%
- Pressure/TCPL modes
- Flow cycling with TCPL
- Proximal flow sensing
- Respiratory Knowledge Portal

**Why VG is important in nRDS**

VG with pressure support ventilation (PSV) results in decreased levels of the inflammatory mediators interleukin-6 (IL-6) and interleukin-8 (IL-8) in neonates with nRDS. Volume targeted strategies, such as VG, have been shown to reduce chronic lung disease and death.

Vyaire helps you care for neonates through:
- Webinars
- Training materials

**REFERENCES**


©2018 Vyaire. Vyaire, the Vyaire Logo and Avea are trademarks of Vyaire Medical, Inc. | CF/802/18/0008(1) (0318)